Tonic modulation of anxiety-like behavior by corticotropin-releasing factor (CRF) type 1 receptor (CRF1) within the medial prefrontal cortex (mPFC) in male mice: role of protein kinase A (PKA)

Horm Behav. 2014 Jul;66(2):247-56. doi: 10.1016/j.yhbeh.2014.05.003. Epub 2014 May 18.

Abstract

The medial prefrontal cortex (mPFC) and the neuropeptide corticotropin-releasing factor (CRF) have recently been receiving more attention from those interested in the neurobiology of anxiety. Here, we investigated the CRF pathway in the modulation of anxiety-like behaviors in male mice exposed to the elevated plus-maze (EPM), through intra-mPFC injections of CRF, CP376395 [N-(1-ethylpropyl)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-4-pyridinamine hydrochloride, a CRF type 1 receptor antagonist (CR F1)] or H-89 [N-[2-[[3-(4-bromophenyl)-2-propenyl]amino]ethyl]-5-isoquinolinesulfonamide dihydrochloride, a protein kinase (PKA) inhibitor]. We also investigated the effects of intra-mPFC injections of H-89 on the behavioral effects induced by CRF. Mice received bilateral intra-mPFC injections of CRF (0, 37.5, 75 or 150pmol), CP376395 (0, 0.75, 1.5 or 3nmol) or H-89 (0, 1.25, 2.5 or 5nmol) and were exposed to the EPM, to record conventional and complementary measures of anxiety for 5min. Results showed that while CRF (75 and 150pmol) produced an anxiogenic-like effect, CP376395 (all doses) and H-89 (5nmol) attenuated anxiety-like behavior. When injected before CRF (150pmol), intra-mPFC H-89 (2.5nmol, a dose devoid of intrinsic effects on anxiety) completely blocked the anxiogenic-like effects of CRF. These results suggest that (i) CRF plays a tonic anxiogenic-like role at CRF1 receptors within the mPFC, since their blockade per se attenuated anxiety indices and (ii) the anxiogenic-like effects following CRF1 receptor activation depend on cAMP/PKA cascade activation in this limbic forebrain area.

Keywords: Anxiety; CRF1 receptor; Corticotrophin-releasing factor (CRF); Elevated plus maze; Medial prefrontal cortex (mPFC); Mice; PKA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminopyridines / pharmacology
  • Animals
  • Anti-Anxiety Agents / pharmacology
  • Anxiety / chemically induced
  • Anxiety / psychology*
  • Corticotropin-Releasing Hormone / pharmacology
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic AMP-Dependent Protein Kinases / physiology*
  • Isoquinolines / pharmacology
  • Male
  • Mice
  • Microinjections
  • Prefrontal Cortex / physiology*
  • Protein Kinase Inhibitors / pharmacology
  • Receptors, Corticotropin-Releasing Hormone / agonists
  • Receptors, Corticotropin-Releasing Hormone / antagonists & inhibitors
  • Receptors, Corticotropin-Releasing Hormone / physiology*
  • Sulfonamides / pharmacology

Substances

  • (3,6-dimethyl-2-(2,4,6-trimethylphenoxy)pyridin-4-yl)(1-ethylpropyl)amine
  • Aminopyridines
  • Anti-Anxiety Agents
  • Isoquinolines
  • Protein Kinase Inhibitors
  • Receptors, Corticotropin-Releasing Hormone
  • Sulfonamides
  • CRF receptor type 1
  • Corticotropin-Releasing Hormone
  • Cyclic AMP-Dependent Protein Kinases
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide